# Equus Total Return, Inc.: financial statements, quarterly

EQS · NYSE · CIK 878932 · [Other](/sectors/other.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/eqs.md) · [Financials](/companies/eqs/financials.md) · [Filings](/companies/eqs/filings.md) · [Insiders](/companies/eqs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/eqs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Selling, general and administrative | $m | [0.0](/filings/0001096906-25-002131.md) | [0.0](/filings/0001096906-25-002129.md) | not reported | not reported | [0.0](/filings/0001096906-25-002103.md) | [0.1](/filings/0001096906-25-002101.md) | [0.0](/filings/0001096906-25-002090.md) | [0.1 d](/filings/0001096906-26-000571.md) | [0.0](/filings/0001096906-25-002095.md) | [0.1](/filings/0001096906-25-002093.md) | [0.0](/filings/0001096906-25-002090.md) | [0.0 d](/filings/0001096906-26-000571.md) |
| Interest expense | $m | [0.0](/filings/0001096906-25-002131.md) | [0.0](/filings/0001096906-25-002129.md) | [0.0](/filings/0001096906-25-002128.md) | [0.0 d](/filings/0001096906-26-000571.md) | [0.0](/filings/0001096906-25-002103.md) | [0.0](/filings/0001096906-25-002101.md) | [0.1](/filings/0001096906-25-002099.md) | [0.0 d](/filings/0001096906-26-000571.md) | [0.0](/filings/0001096906-25-002095.md) | [0.1](/filings/0001096906-25-002093.md) | [0.4](/filings/0001096906-25-002090.md) | [0.2 d](/filings/0001096906-26-000571.md) |
| Income tax | $m | [0.0](/filings/0001096906-25-002103.md) | [0.0](/filings/0001096906-25-002129.md) | [0.0](/filings/0001096906-25-002128.md) | [0.0 d](/filings/0001096906-26-000571.md) | [0.0](/filings/0001096906-25-002103.md) | [0.0](/filings/0001096906-25-002101.md) | [0.0](/filings/0001096906-25-002099.md) | [0.0 d](/filings/0001096906-26-000571.md) | [0.0](/filings/0001096906-25-002095.md) | [0.0](/filings/0001096906-25-002093.md) | [0.0](/filings/0001096906-25-002090.md) | [0.0 d](/filings/0001096906-26-000571.md) |
| Net income | $m | [(1.1)](/filings/0001096906-25-002131.md) | [5.9](/filings/0001096906-25-002129.md) | [7.1](/filings/0001096906-25-002128.md) | [1.1 d](/filings/0001096906-26-000571.md) | [(2.4)](/filings/0001096906-25-002103.md) | [3.9](/filings/0001096906-25-002101.md) | [(9.6)](/filings/0001096906-25-002099.md) | [(10.7) d](/filings/0001096906-26-000571.md) | [3.9](/filings/0001096906-25-002095.md) | [(0.1)](/filings/0001096906-25-002093.md) | [(8.1)](/filings/0001096906-25-002090.md) | [(9.9) d](/filings/0001096906-26-000571.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001096906-25-002131.md) | [0.44](/filings/0001096906-25-002129.md) | [0.52](/filings/0001096906-25-002128.md) | not reported | [(0.17)](/filings/0001096906-25-002103.md) | [0.29](/filings/0001096906-25-002093.md) | [(0.70)](/filings/0001096906-25-002099.md) | not reported | [0.25](/filings/0001096906-25-002095.md) | [(0.01)](/filings/0001096906-25-002093.md) | [(0.59)](/filings/0001096906-25-002090.md) | not reported |
| Basic EPS | $ per share | not reported | [0.44](/filings/0001096906-25-002101.md) | not reported | not reported | [(0.17)](/filings/0001096906-25-002095.md) | [0.29](/filings/0001096906-25-002101.md) | [(0.70)](/filings/0001096906-25-002090.md) | not reported | [0.30](/filings/0001096906-25-002095.md) | [(0.01)](/filings/0001096906-25-002093.md) | [(0.59)](/filings/0001096906-25-002090.md) | not reported |

- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [17.7](/filings/0001096906-25-002131.md) | [16.4](/filings/0001096906-25-002129.md) | [13.7](/filings/0001096906-25-002128.md) | [6.5](/filings/0001096906-26-000571.md) | [3.1](/filings/0001096906-25-002103.md) | [1.9](/filings/0001096906-25-002101.md) | [1.1](/filings/0001096906-25-002099.md) | [0.3](/filings/0001096906-26-000571.md) | [0.7](/filings/0001096906-25-002095.md) | [0.1](/filings/0001096906-25-002093.md) | [0.3](/filings/0001096906-25-002090.md) | [0.1](/filings/0001096906-26-000571.md) |
| Total assets | $m | [44.5](/filings/0001096906-25-002131.md) | [53.1](/filings/0001096906-25-002129.md) | [65.5](/filings/0001096906-25-002128.md) | [93.5](/filings/0001096906-25-002127.md) | [99.1](/filings/0001096906-25-002103.md) | [104](/filings/0001096906-25-002101.md) | [95.5](/filings/0001096906-25-002099.md) | [29.9](/filings/0001096906-26-000571.md) | [36.5](/filings/0001096906-25-002095.md) | [37.1](/filings/0001096906-25-002093.md) | [31.4](/filings/0001096906-25-002090.md) | [21.3](/filings/0001096906-26-000571.md) |
| Total liabilities | $m | [10.4](/filings/0001096906-25-002131.md) | [13.0](/filings/0001096906-25-002129.md) | [18.4](/filings/0001096906-25-002128.md) | [45.3](/filings/0001096906-25-002127.md) | [53.2](/filings/0001096906-25-002103.md) | [54.1](/filings/0001096906-25-002101.md) | [55.3](/filings/0001096906-25-002099.md) | [0.4](/filings/0001096906-26-000571.md) | [2.3](/filings/0001096906-25-002095.md) | [3.0](/filings/0001096906-25-002093.md) | [4.9](/filings/0001096906-25-002090.md) | [4.8](/filings/0001096906-26-000571.md) |
| Shareholders' equity | $m | [34.1](/filings/0001096906-25-002131.md) | [40.1](/filings/0001096906-25-002129.md) | [47.1](/filings/0001096906-25-002128.md) | [48.3](/filings/0001096906-26-000571.md) | [45.9](/filings/0001096906-25-002103.md) | [49.8](/filings/0001096906-25-002101.md) | [40.2](/filings/0001096906-25-002099.md) | [29.5](/filings/0001096906-26-000571.md) | [34.2](/filings/0001096906-25-002095.md) | [34.1](/filings/0001096906-25-002093.md) | [26.5](/filings/0001096906-25-002090.md) | [16.6](/filings/0001096906-26-000571.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.5)](/filings/0001096906-25-002131.md) | [(4.3) d](/filings/0001096906-25-002129.md) | [(7.7) d](/filings/0001096906-25-002128.md) | [(33.9) d](/filings/0001096906-26-000571.md) | [(11.4)](/filings/0001096906-25-002103.md) | [(2.1) d](/filings/0001096906-25-002101.md) | [(1.8) d](/filings/0001096906-25-002099.md) | [53.6 d](/filings/0001096906-26-000571.md) | [(1.6)](/filings/0001096906-25-002095.md) | [(0.6) d](/filings/0001096906-25-002093.md) | [0.3 d](/filings/0001096906-25-002090.md) | [(0.2) d](/filings/0001096906-26-000571.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [13.5](/filings/0001096906-25-002136.md) | [13.5](/filings/0001096906-25-002135.md) | [0.0](/filings/0001096906-25-002134.md) | [13.5](/filings/0001096906-25-002131.md) | [13.5](/filings/0001096906-25-002129.md) | [13.5](/filings/0001096906-25-002128.md) | [13.6](/filings/0001096906-25-002103.md) | [13.6](/filings/0001096906-25-002093.md) | [13.6](/filings/0001096906-25-002099.md) | [15.5](/filings/0001096906-25-002095.md) | [13.6](/filings/0001096906-25-002093.md) | [13.7](/filings/0001096906-25-002090.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 13,966,696 at 2026-04-17, from the cover of the [10-K/A filed 2026-04-20](/filings/0001096906-26-000571.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.